TG Therapeutics raises 2026 revenue guidance, outlines subcutaneous BRIUMVI timeline
TG Therapeutics lifted full-year 2026 global revenue guidance to about $1 billion and pointed to Phase 3 subcutaneous BRIUMVI data expected around year-end or early 2027.
TG Therapeutics reported third-quarter 2026 results on November 9, 2026, and raised its financial guidance for the year. The company said it now expects full-year 2026 total global revenue of approximately $1 billion, up from approximately $950 million, and raised full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915 to $920 million from $890 to $905 million.1
On the pipeline, TG Therapeutics presented data at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. In the Phase 3 ENHANCE trial, the company said positive results showed bioequivalent drug exposure between the currently approved two-infusion BRIUMVI initiation regimen and a consolidated single 600mg initiation infusion, with comparable infusion-related reactions and no Grade 3 or higher reactions observed.1 For subcutaneous BRIUMVI, a Phase 1 trial showed mean bioavailability greater than 60% relative to IV administration, with pharmacokinetic modeling supporting the quarterly dosing regimen being evaluated in the fully enrolled Phase 3 trial, and top-line Phase 3 data are expected by year-end 2026 or early 2027.1
Chief Executive Michael S. Weiss said the company sees a series of important catalysts over the next 18 to 24 months, including pivotal Phase 3 subcutaneous BRIUMVI results expected around year-end or early 2027, a potential launch of simplified IV initiation in mid-2027, additional pipeline data, and a potential subcutaneous BRIUMVI launch in 2028.1
Elsewhere in the pipeline, the company announced positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis and initiated a potentially registration-directed randomized Phase 2 trial of IV BRIUMVI as maintenance therapy after induction with efgartigimod in adult MG patients,1 and separately initiated a Phase 2 trial of BRIUMVI in adults with treatment-resistant schizophrenia.1
On capital, the company reported cash, cash equivalents and investment securities of $556.7 million as of September 30, 2026, and said it anticipates that balance, combined with projected BRIUMVI revenues, will be sufficient to fund its business under its current operating plan.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.